STOCK TITAN
  1. Home
  2. News
  3. HALO

Halozyme Therapeutics Inc. - HALO STOCK NEWS

Welcome to our dedicated news page for Halozyme Therapeutics (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Halozyme Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Halozyme Therapeutics's position in the market.

News
HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
Rhea-AI Summary
Halozyme Therapeutics, Inc. reported a 15% YoY increase in royalty revenue to a record $114.4 million. They also announced the acceleration of the remaining $250 million share repurchase through ASR. GAAP diluted EPS was $0.61 and non-GAAP diluted EPS was $0.75. The company maintained its revenue guidance and raised its 2023 EBITDA guidance to $430-$445 million and non-GAAP EPS guidance to $2.70-$2.80.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.04%
Tags
earnings
-
News
Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease
Rhea-AI Summary
Halozyme Therapeutics announces a collaboration and license agreement with Acumen Pharmaceuticals for the use of their ENHANZE® drug delivery technology in the development of ACU193, a monoclonal antibody candidate for the treatment of early Alzheimer's disease. Acumen will make upfront and milestone payments to Halozyme, and Halozyme will receive royalties on net sales of commercialized medicines with the ENHANZE® technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
-
News
Halozyme To Report Third Quarter 2023 Financial and Operating Results
Rhea-AI Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will release its third quarter 2023 financial and operating results on November 6, 2023. A conference call to discuss the results will be held on the same day. The conference call can be accessed via pre-registration and a webcast and replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
conferences earnings
News
Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Rhea-AI Summary
Bristol Myers Squibb (BMS) reports positive results from Phase 3 trial of subcutaneous nivolumab in renal cell carcinoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
clinical trial
-
News
Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference
Rhea-AI Summary
Halozyme presents positive results of a clinical study demonstrating successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
partnership clinical trial
-
News
Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery
Rhea-AI Summary
Halozyme announces positive results of a clinical study demonstrating successful subcutaneous administration of a biologic co-formulated with ENHANZE® in 30 seconds
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
clinical trial
News
Halozyme to Present at Upcoming Investor Conferences
Rhea-AI Summary
Halozyme CEO to present at investor conferences: Wells Fargo Healthcare Conference, H.C. Wainwright Global Investment Conference, Morgan Stanley Global Healthcare Conference, and Baird Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
conferences
-
News
HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
Rhea-AI Summary
Halozyme Therapeutics, Inc. (HALO) reported a 45% YOY increase in revenue to $221.0 million, with GAAP diluted EPS of $0.56 and Non-GAAP diluted EPS of $0.741. Royalty revenue increased 31% YOY to a record $111.7 million. The company raised 2023 Non-GAAP diluted EPS guidance to $2.65-$2.75 and updated revenue guidance to $825-$845 million, representing 25-28% YOY growth, and EBITDA guidance to $420-$440 million, representing >30% YOY growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
earnings
-
News
Halozyme To Report Second Quarter 2023 Financial and Operating Results
Rhea-AI Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced the release of its second quarter 2023 financial and operating results on Tuesday, August 8, 2023, with a conference call to discuss the results. The live webcast and replay of the conference call will be available through the 'Investors' section of Halozyme's corporate website at www.halozyme.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
conferences earnings
News
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
Rhea-AI Summary
Halozyme Therapeutics announces positive topline data from the ADHERE study for VYVGART Hytrulo in adults with CIDP
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
none
Stock HALO logo
Halozyme Therapeutics Inc.

Nasdaq:HALO

HALO Rankings

#1200 Ranked by Market Cap
#3871 Ranked by Stock Gains
N/A Ranked by Dividends

HALO Stock Data

4.91B
125.47M
1.08%
100.28%
6.21%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
San Diego

About HALO

we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies